FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2999727144> ?p ?o ?g. }

• W2999727144 abstract "ABSTRACT Background PST with taxanes, anthracycline-containing regimens and T showed a high percentage of pathologic complete response (pCR); T administered concurrently with chemotherapy is more effective, but the combination with anthracyclines may be at risk of cardiotoxicity. The present study evaluates efficacy and toxicity of T administered concurrently with a sequential regimen of D followed by EC in neoadjuvant setting. Materials and methods This phase II single stage trial is enrolling pts with cT2-T4, N0-2, M0, Her-2 positive (IHC 3+ or 2+ amplified) breast cancer. A core biopsy is required prior treatment start to evaluate hormonal receptors, Ki67, topoisomerase II, Her-2, with re-evaluation of these parameters, whenever possible, at definite surgery. LVEF is evaluated before and during treatment. Blood samples are collected at baseline for evaluation of 9 genetic polymorphisms related to higher risk of developing cardiac toxicity. We are quantitatively evaluating gene copy number by multiple ligand probe amplification (MLPA), PTEN, p-Akt, p-MAPK, and PIK3CA mutations. Pts receive 4 cycles of D (100mg/m2) plus T (loading dose 8mg/kg followed by 6mg/kg), followed by 4 cycles of EC (120/600mg/m2) plus T, every 3 weeks. Definite surgery is planned at the end of PST, and standard radiotherapy and hormonal adjuvant treatment in case of positive hormonal receptors are given; adjuvant T is given for 6 months. The primary objective of the trial is pCR (absence of invasive tumor cells in the breast and axilla); secondary objectives are cardiac safety, toxicity, disease-free survival. The planned sample size is 42 pts. Results To date, 29 pts have been enrolled; median age is 45 years, pre/postmenopausal 22/7, ER and/or PgR positive in 16 pts. 27 pts are evaluable for pathological response: we observed 20 pCR (74%, 95%C.I, 57.5-90.6). Grade 3-4 neutropenia was the most frequent toxicity, encountered in 75% of the pts, other toxicities were mild to moderate. No clinical cardiotoxicity was observed. Conclusions At preliminary analysis, PST with sequential administration of D followed by EC, given concurrently with T, appears to be very active and safe in stage II-III breast cancer pts. Disclosure All authors have declared no conflicts of interest." @default.
• W2999727144 created "2020-01-23" @default.
• W2999727144 creator A5004308386 @default.
• W2999727144 creator A5004830992 @default.
• W2999727144 creator A5019614566 @default.
• W2999727144 creator A5023710153 @default.
• W2999727144 creator A5025243663 @default.
• W2999727144 creator A5026439843 @default.
• W2999727144 creator A5026785056 @default.
• W2999727144 creator A5054042910 @default.
• W2999727144 creator A5062971539 @default.
• W2999727144 creator A5091117889 @default.
• W2999727144 date "2012-09-01" @default.
• W2999727144 modified "2023-09-28" @default.
• W2999727144 title "Phase II Trial of Primary Systemic Therapy (PST) with Docetaxel (D) Followed by High-Dose Epirubicin in Combination with Cyclophosphamide (EC) Plus Concurrent Trastuzumab (T) For Stage II-III HER-2 Positive Breast Cancer Patients (PTS)" @default.
• W2999727144 doi "https://doi.org/10.1016/s0923-7534(20)32973-2" @default.
• W2999727144 hasPublicationYear "2012" @default.
• W2999727144 type Work @default.
• W2999727144 sameAs 2999727144 @default.
• W2999727144 citedByCount "0" @default.
• W2999727144 crossrefType "journal-article" @default.
• W2999727144 hasAuthorship W2999727144A5004308386 @default.
• W2999727144 hasAuthorship W2999727144A5004830992 @default.
• W2999727144 hasAuthorship W2999727144A5019614566 @default.
• W2999727144 hasAuthorship W2999727144A5023710153 @default.
• W2999727144 hasAuthorship W2999727144A5025243663 @default.
• W2999727144 hasAuthorship W2999727144A5026439843 @default.
• W2999727144 hasAuthorship W2999727144A5026785056 @default.
• W2999727144 hasAuthorship W2999727144A5054042910 @default.
• W2999727144 hasAuthorship W2999727144A5062971539 @default.
• W2999727144 hasAuthorship W2999727144A5091117889 @default.
• W2999727144 hasBestOaLocation W29997271441 @default.
• W2999727144 hasConcept C121608353 @default.
• W2999727144 hasConcept C126322002 @default.
• W2999727144 hasConcept C126894567 @default.
• W2999727144 hasConcept C141071460 @default.
• W2999727144 hasConcept C143998085 @default.
• W2999727144 hasConcept C2776694085 @default.
• W2999727144 hasConcept C2776802502 @default.
• W2999727144 hasConcept C2779786085 @default.
• W2999727144 hasConcept C2780835546 @default.
• W2999727144 hasConcept C2781190966 @default.
• W2999727144 hasConcept C2781413609 @default.
• W2999727144 hasConcept C530470458 @default.
• W2999727144 hasConcept C71924100 @default.
• W2999727144 hasConcept C90924648 @default.
• W2999727144 hasConceptScore W2999727144C121608353 @default.
• W2999727144 hasConceptScore W2999727144C126322002 @default.
• W2999727144 hasConceptScore W2999727144C126894567 @default.
• W2999727144 hasConceptScore W2999727144C141071460 @default.
• W2999727144 hasConceptScore W2999727144C143998085 @default.
• W2999727144 hasConceptScore W2999727144C2776694085 @default.
• W2999727144 hasConceptScore W2999727144C2776802502 @default.
• W2999727144 hasConceptScore W2999727144C2779786085 @default.
• W2999727144 hasConceptScore W2999727144C2780835546 @default.
• W2999727144 hasConceptScore W2999727144C2781190966 @default.
• W2999727144 hasConceptScore W2999727144C2781413609 @default.
• W2999727144 hasConceptScore W2999727144C530470458 @default.
• W2999727144 hasConceptScore W2999727144C71924100 @default.
• W2999727144 hasConceptScore W2999727144C90924648 @default.
• W2999727144 hasLocation W29997271441 @default.
• W2999727144 hasOpenAccess W2999727144 @default.
• W2999727144 hasPrimaryLocation W29997271441 @default.
• W2999727144 isParatext "false" @default.
• W2999727144 isRetracted "false" @default.
• W2999727144 magId "2999727144" @default.
• W2999727144 workType "article" @default.